José María Martínez-Jabaloyas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
José María Martínez-Jabaloyas has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Panach-Navarrete
Department of Urology, University Clinic Hospital of Valencia, INCLIVA, Health Research Institute, University of Valencia Faculty of Medicine and Odontology, Valencia, Spain
9 shared publications Daniel Monleón-Salvado
Department of Pathology, Medicine and Odontology Faculty, University of Valencia, Research Unit, INCLIVA Health Research Institute, CP, Valencia, Spain
2 shared publications- Daniel Ortiz-Seller
Pharmacology Department, Faculty of Medicine, University of Valencia, Valencia, Spain
2 shared publications Francisco García-Morata
Department of Urology. University Clinic Hospital of Valencia. INCLIVA, Health Research Institute, Facultat de Medicina i Odontologia. Universitat de València., CP, Valencia, Spain
2 shared publicationsJosé Manuel Morales-Tatay
Department of Pathology, Medicine and Odontology Faculty, University of Valencia, Research Unit, INCLIVA Health Research Institute, CP, Valencia, Spain
2 shared publicationsLorena Valls-González
2 shared publications
Latest Publications
- Open Access
- 13 October 2026
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 52, 1-9
Metabolic Analysis Using HR-MAS in Prostate Tissue to Predict Biochemical Recurrence in Prostate Cancer
Objective: In this study, nuclear magnetic resonance (NMR) spectroscopy was used in prostate tissue to gather novel data on biomarkers that could predict biochemical recurrence in prostate cancer. Methods: Prostate tissue cores were collected from individuals who presented to our institution for transrectal biopsy. After acquiring all the spectra using a Bruker Avance III DRX 600 spectrometer, tissue specimens were subjected to routine histology to confirm the presence or absence of prostate cancer. Univariate and multivariate analyses with metabolic and clinical variables were performed to predict biochemical recurrence in men treated for prostate cancer. Results: Data were collected from 70 patients treated for prostate cancer, 16 of whom developed biochemical recurrence within 5 years of treatment, with an average time to diagnosed recurrence of 25.68 ± 15.39 months. Metabolites detected in tissue, such as O-phosphoethanolamine, ethanol, succinate, or ascorbate, together with ISUP grades of 4 and 5, formed a predictive model for biochemical recurrence with an area under the curve (AUC) of 0.88, a specificity of 91%, and a negative predictive value (NPV) of 88%. Conclusion: In prostate cancer patients who have undergone treatment, metabolomic evaluation through HR-MAS can serve as a predictor of biochemical recurrence. Metabolites such as O-phosphoethanolamine, ethanol, succinate, ascorbate, and cysteine are useful in this context. Adding another clinical variable, such as ISUP grades 4 and 5, in prostate histology to these metabolites forms a predictive model capable of predicting biochemical recurrence in prostate cancer. Cite this article as: Panach-Navarrete J, González-Marrachelli V, Morales-Tatay JM, et al. Metabolic analysis using HR-MAS in prostate tissue to predict biochemical recurrence in prostate cancer. Urol Res Pract. 2026;52, doi:10.5152/tud.2026.25102
- 13 October 2026
- Published by AVES YAYINCILIK A.Ş. in Urology Research and Practice
- Vol. 52, 1-9
Open AccessMetabolic Analysis Using HR-MAS in Prostate Tissue to Predict Biochemical Recurrence in Prostate Cancer
Objective: In this study, nuclear magnetic resonance (NMR) spectroscopy was used in prostate tissue to gather novel data on biomarkers that could predict biochemical recurrence in prostate cancer. Methods: Prostate tissue cores were collected from individuals who presented to our institution for transrectal biopsy. After acquiring all the spectra using a Bruker Avance III DRX 600 spectrometer, tissue specimens were subjected to routine histology to confirm the presence or absence of prostate cancer. Univariate and multivariate analyses with metabolic and clinical variables were performed to predict biochemical recurrence in men treated for prostate cancer. Results: Data were collected from 70 patients treated for prostate cancer, 16 of whom developed biochemical recurrence within 5 years of treatment, with an average time to diagnosed recurrence of 25.68 ± 15.39 months. Metabolites detected in tissue, such as O-phosphoethanolamine, ethanol, succinate, or ascorbate, together with ISUP grades of 4 and 5, formed a predictive model for biochemical recurrence with an area under the curve (AUC) of 0.88, a specificity of 91%, and a negative predictive value (NPV) of 88%. Conclusion: In prostate cancer patients who have undergone treatment, metabolomic evaluation through HR-MAS can serve as a predictor of biochemical recurrence. Metabolites such as O-phosphoethanolamine, ethanol, succinate, ascorbate, and cysteine are useful in this context. Adding another clinical variable, such as ISUP grades 4 and 5, in prostate histology to these metabolites forms a predictive model capable of predicting biochemical recurrence in prostate cancer. Cite this article as: Panach-Navarrete J, González-Marrachelli V, Morales-Tatay JM, et al. Metabolic analysis using HR-MAS in prostate tissue to predict biochemical recurrence in prostate cancer. Urol Res Pract. 2026;52, doi:10.5152/tud.2026.25102
- Open Access
- 1 April 2026
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 15 (4) , 138
Paclitaxel-coated balloon adjunct for benign ureteral and ureteroenteric strictures: a narrative review and translational proposal for enhanced endourological patency
Conventional endourological techniques, including balloon dilation and endoureterotomy, offer mechanical luminal relief but do not modulate the fibroproliferative cascade that drives restenosis. Paclitaxel-coated balloons, widely validated in vascular and urethral interventions, deliver localized antiproliferative therapy with minimal systemic exposure. Their mechanism—selective drug uptake into the urothelium, submucosa, and muscularis—may theoretically enhance long-term patency after endoscopic management. This review aims to summarize the translational rationale, mechanistic basis, and technical application of paclitaxel- and paclitaxel-dextran-coated balloons for benign ureteral and ureteroenteric strictures, and to contextualize their potential role within contemporary endourology. A narrative, non-systematic synthesis was performed integrating data from preclinical ureteral pharmacokinetic studies, vascular and urethral drug-coated balloons (DCBs) experience, and early human reports in benign ureteral and ureteroenteric strictures. The review emphasizes device characteristics, inflation parameters, drug-tissue interactions, and procedural workflows relevant to translational endourological practice. Experimental models demonstrate time-dependent paclitaxel penetration across ureteral layers and sustained tissue residence. Early clinical experience—including a prospective pilot study and recent case-based observations—indicates that DCB use is technically feasible, exhibits an acceptable safety profile, and may achieve encouraging short-term radiologic patency. Cross-territory evidence from vascular and urethral platforms provides additional mechanistic justification for translational use in the ureter. Paclitaxel-based DCBs represent a technically feasible adjunct with a strong biological rationale for the endourological management of benign ureteral and ureteroenteric strictures. While mechanistic foundations and preliminary clinical signals are promising, rigorous prospective studies are required to define optimal technique, inflation parameters, patient selection, pharmacokinetics, and long-term outcomes before widespread adoption.
- 1 April 2026
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 15 (4) , 138
Open AccessPaclitaxel-coated balloon adjunct for benign ureteral and ureteroenteric strictures: a narrative review and translational proposal for enhanced endourological patency
Conventional endourological techniques, including balloon dilation and endoureterotomy, offer mechanical luminal relief but do not modulate the fibroproliferative cascade that drives restenosis. Paclitaxel-coated balloons, widely validated in vascular and urethral interventions, deliver localized antiproliferative therapy with minimal systemic exposure. Their mechanism—selective drug uptake into the urothelium, submucosa, and muscularis—may theoretically enhance long-term patency after endoscopic management. This review aims to summarize the translational rationale, mechanistic basis, and technical application of paclitaxel- and paclitaxel-dextran-coated balloons for benign ureteral and ureteroenteric strictures, and to contextualize their potential role within contemporary endourology. A narrative, non-systematic synthesis was performed integrating data from preclinical ureteral pharmacokinetic studies, vascular and urethral drug-coated balloons (DCBs) experience, and early human reports in benign ureteral and ureteroenteric strictures. The review emphasizes device characteristics, inflation parameters, drug-tissue interactions, and procedural workflows relevant to translational endourological practice. Experimental models demonstrate time-dependent paclitaxel penetration across ureteral layers and sustained tissue residence. Early clinical experience—including a prospective pilot study and recent case-based observations—indicates that DCB use is technically feasible, exhibits an acceptable safety profile, and may achieve encouraging short-term radiologic patency. Cross-territory evidence from vascular and urethral platforms provides additional mechanistic justification for translational use in the ureter. Paclitaxel-based DCBs represent a technically feasible adjunct with a strong biological rationale for the endourological management of benign ureteral and ureteroenteric strictures. While mechanistic foundations and preliminary clinical signals are promising, rigorous prospective studies are required to define optimal technique, inflation parameters, patient selection, pharmacokinetics, and long-term outcomes before widespread adoption.
- 1 January 2026
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 79 (7) , 1249-1258
Erectile Function and Genital Self-Perception in Young Adults After Childhood Hypospadias Repair: A Case–Control Study
Background: Long-term evidence on sexual function and genital self-perception in men operated for hypospadias in childhood remains heterogeneous. This exploratory study evaluated erectile function, genital self-perception, and sexual quality of life in young adults with prior hypospadias repair compared with healthy male volunteers. Methods: Exploratory case–control study compared 17 adult men who underwent hypospadias repair before the age of 4 years between 1995 and 2005 with 19 healthy male volunteers of similar age, without known urogenital anomalies, sexual dysfunction, or relevant cardiometabolic disease. Participants anonymously completed the five-item International Index of Erectile Function (IIEF-5), the Hypospadias Objective Penile Evaluation (HOPE), administered as a self-report measure of perceived penile appearance, and the Sexual Quality of Life–Male (SQoL-M) questionnaire. Multivariable regression analyses were adjusted for age and relationship status. Results: Most cases had distal hypospadias (82.3%). Age did not differ significantly between groups (25.6 ± 3.8 vs 27.0 ± 1.6 years; p = 0.288). IIEF-5 scores were lower in cases (21.8 ± 3.1 vs 24.5 ± 0.7; p = 0.002), though both groups remained within ranges consistent with absent or mild erectile dysfunction. HOPE scores were also lower in cases (48.5 ± 6.1 vs 58.1 ± 2.4; p < 0.001), driven by differences in meatal configuration, skin coverage, and torsion. SQoL-M did not differ significantly. Group status was the sole independent predictor of IIEF-5 and HOPE scores. Conclusions: In a predominantly distal cohort, men after childhood hypospadias repair showed statistically significant but clinically modest differences in erectile function scores and lower perceived penile appearance compared with healthy controls, with sexual quality of life preserved. These findings should be interpreted in the context of the small sample size and predominance of distal forms and support consideration of psychosexual assessment within transitional urology programmes. Larger multicentre studies are warranted to further clarify long-term outcomes and risk factors.
- 1 January 2026
- Published by Archivos Espanoles de Urologia in Archivos Espanoles de Urologia
- Vol. 79 (7) , 1249-1258
Erectile Function and Genital Self-Perception in Young Adults After Childhood Hypospadias Repair: A Case–Control Study
Background: Long-term evidence on sexual function and genital self-perception in men operated for hypospadias in childhood remains heterogeneous. This exploratory study evaluated erectile function, genital self-perception, and sexual quality of life in young adults with prior hypospadias repair compared with healthy male volunteers. Methods: Exploratory case–control study compared 17 adult men who underwent hypospadias repair before the age of 4 years between 1995 and 2005 with 19 healthy male volunteers of similar age, without known urogenital anomalies, sexual dysfunction, or relevant cardiometabolic disease. Participants anonymously completed the five-item International Index of Erectile Function (IIEF-5), the Hypospadias Objective Penile Evaluation (HOPE), administered as a self-report measure of perceived penile appearance, and the Sexual Quality of Life–Male (SQoL-M) questionnaire. Multivariable regression analyses were adjusted for age and relationship status. Results: Most cases had distal hypospadias (82.3%). Age did not differ significantly between groups (25.6 ± 3.8 vs 27.0 ± 1.6 years; p = 0.288). IIEF-5 scores were lower in cases (21.8 ± 3.1 vs 24.5 ± 0.7; p = 0.002), though both groups remained within ranges consistent with absent or mild erectile dysfunction. HOPE scores were also lower in cases (48.5 ± 6.1 vs 58.1 ± 2.4; p < 0.001), driven by differences in meatal configuration, skin coverage, and torsion. SQoL-M did not differ significantly. Group status was the sole independent predictor of IIEF-5 and HOPE scores. Conclusions: In a predominantly distal cohort, men after childhood hypospadias repair showed statistically significant but clinically modest differences in erectile function scores and lower perceived penile appearance compared with healthy controls, with sexual quality of life preserved. These findings should be interpreted in the context of the small sample size and predominance of distal forms and support consideration of psychosexual assessment within transitional urology programmes. Larger multicentre studies are warranted to further clarify long-term outcomes and risk factors.
- Open Access
- 3 December 2025
- Published by Elsevier in Urology Case Reports
- Vol. 64, 103302
Multimodal treatment for failed pyeloplasty: Description of a new technique
- 3 December 2025
- Published by Elsevier in Urology Case Reports
- Vol. 64, 103302
Open AccessMultimodal treatment for failed pyeloplasty: Description of a new technique
- Open Access
- 16 November 2025
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (2) , 125.e1-125.e10
Urine metabolic analysis as a noninvasive method to diagnose prostate cancer
- 16 November 2025
- Published by Elsevier in Urologic Oncology: Seminars and Original Investigations
- Vol. 44 (2) , 125.e1-125.e10
Open AccessUrine metabolic analysis as a noninvasive method to diagnose prostate cancer
- Open Access
- 1 November 2025
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 14 (11) , 3708-3717
Urine metabolic analysis as a non-invasive method to predict biochemical recurrence in prostate cancer
Background: Metabolomics has proven to be a useful science for obtaining biomarkers in prostate cancer. In this work, urine samples were analyzed by nuclear magnetic resonance (NMR) spectroscopy to identify potential urinary biomarkers associated with biochemical recurrence in prostate cancer. Methods: Urine samples were obtained from patients undergoing transrectal prostate biopsy after prostate massage. Patients were classified as with or without biochemical recurrence after having received prostate cancer treatment. All spectra were acquired using a Bruker Avance III DRX 600 spectrometer. Univariate and multivariate analysis were performed with metabolites and clinical variables to predict tumor presence. Results: Data were collected from 70 patients treated for prostate cancer, 16 of whom developed biochemical recurrence within 5 years following treatment, with an average time to diagnosed recurrence of 25.68±15.39 months. After establishing a predictive model with the 25 most influential metabolites in Partial Least Squares Discriminant Analysis (PLS-DA analysis), a predictive model of biochemical recurrence was obtained with an area under the curve of 0.95, a sensitivity of 80%, specificity of 98%, positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 96%. Metabolites derived from amino acid metabolism and glycolysis featured most predominantly in this model. Conclusions: The metabolic profile in urine can be used to construct a model with good discrimination for predicting the development of biochemical recurrence. The molecules highlighted herein frequently belong to amino acid metabolism and glycolysis.
- 1 November 2025
- Published by AME Publishing Company in Translational Andrology and Urology
- Vol. 14 (11) , 3708-3717
Open AccessUrine metabolic analysis as a non-invasive method to predict biochemical recurrence in prostate cancer
Background: Metabolomics has proven to be a useful science for obtaining biomarkers in prostate cancer. In this work, urine samples were analyzed by nuclear magnetic resonance (NMR) spectroscopy to identify potential urinary biomarkers associated with biochemical recurrence in prostate cancer. Methods: Urine samples were obtained from patients undergoing transrectal prostate biopsy after prostate massage. Patients were classified as with or without biochemical recurrence after having received prostate cancer treatment. All spectra were acquired using a Bruker Avance III DRX 600 spectrometer. Univariate and multivariate analysis were performed with metabolites and clinical variables to predict tumor presence. Results: Data were collected from 70 patients treated for prostate cancer, 16 of whom developed biochemical recurrence within 5 years following treatment, with an average time to diagnosed recurrence of 25.68±15.39 months. After establishing a predictive model with the 25 most influential metabolites in Partial Least Squares Discriminant Analysis (PLS-DA analysis), a predictive model of biochemical recurrence was obtained with an area under the curve of 0.95, a sensitivity of 80%, specificity of 98%, positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 96%. Metabolites derived from amino acid metabolism and glycolysis featured most predominantly in this model. Conclusions: The metabolic profile in urine can be used to construct a model with good discrimination for predicting the development of biochemical recurrence. The molecules highlighted herein frequently belong to amino acid metabolism and glycolysis.
- 7 May 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 20 (4) , 730.e1-730.e5
Prospective comparison of two methods for correct ureteral stent placement in pediatric laparoscopic pyeloplasty
- 7 May 2024
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 20 (4) , 730.e1-730.e5
Prospective comparison of two methods for correct ureteral stent placement in pediatric laparoscopic pyeloplasty
- Open Access
- 11 January 2024
- Published by Wiley in The Prostate
- Vol. 84 (6) , 549-559
Metabolic analysis using HR‐MAS in prostate tissue for prostate cancer diagnosis
Introduction: In this study we used nuclear magnetic resonance spectroscopy in prostate tissue to provide new data on potential biomarkers of prostate cancer in patients eligible for prostate biopsy.Material and Methods: Core needle prostate tissue samples were obtained. After acquiring all the spectra using a Bruker Avance III DRX 600 spectrometer, tissue samples were subjected to routine histology to confirm presence or absence of prostate cancer. Univariate and multivariate analyses with metabolic and clinical variables were performed to predict the occurrence of prostate cancer.Results: A total of 201 patients, were included in the study. Of all cores subjected to high‐resolution magic angle spinning (HR‐MAS) followed by standard histological study, 56 (27.8%) tested positive for carcinoma. According to HR‐MAS probe analysis, metabolic pathways such as glycolysis, the Krebs cycle, and the metabolism of different amino acids were associated with presence of prostate cancer. Metabolites detected in tissue such as citrate or glycerol‐3‐phosphocholine, together with prostate volume and suspicious rectal examination, formed a predictive model for prostate cancer in tissue with an area under the curve of 0.87, a specificity of 94%, a positive predictive value of 80% and a negative predictive value of 84%.Conclusions: Metabolomics using HR‐MAS analysis can uncover a specific metabolic fingerprint of prostate cancer in prostate tissue, using a tissue core obtained by transrectal biopsy. This specific fingerprint is based on levels of citrate, glycerol‐3‐phosphocholine, glycine, carnitine, and 0‐phosphocholine. Several clinical variables, such as suspicious digital rectal examination and prostate volume, combined with these metabolites, form a predictive model to diagnose prostate cancer that has shown encouraging results.
- 11 January 2024
- Published by Wiley in The Prostate
- Vol. 84 (6) , 549-559
Open AccessMetabolic analysis using HR‐MAS in prostate tissue for prostate cancer diagnosis
Introduction: In this study we used nuclear magnetic resonance spectroscopy in prostate tissue to provide new data on potential biomarkers of prostate cancer in patients eligible for prostate biopsy.Material and Methods: Core needle prostate tissue samples were obtained. After acquiring all the spectra using a Bruker Avance III DRX 600 spectrometer, tissue samples were subjected to routine histology to confirm presence or absence of prostate cancer. Univariate and multivariate analyses with metabolic and clinical variables were performed to predict the occurrence of prostate cancer.Results: A total of 201 patients, were included in the study. Of all cores subjected to high‐resolution magic angle spinning (HR‐MAS) followed by standard histological study, 56 (27.8%) tested positive for carcinoma. According to HR‐MAS probe analysis, metabolic pathways such as glycolysis, the Krebs cycle, and the metabolism of different amino acids were associated with presence of prostate cancer. Metabolites detected in tissue such as citrate or glycerol‐3‐phosphocholine, together with prostate volume and suspicious rectal examination, formed a predictive model for prostate cancer in tissue with an area under the curve of 0.87, a specificity of 94%, a positive predictive value of 80% and a negative predictive value of 84%.Conclusions: Metabolomics using HR‐MAS analysis can uncover a specific metabolic fingerprint of prostate cancer in prostate tissue, using a tissue core obtained by transrectal biopsy. This specific fingerprint is based on levels of citrate, glycerol‐3‐phosphocholine, glycine, carnitine, and 0‐phosphocholine. Several clinical variables, such as suspicious digital rectal examination and prostate volume, combined with these metabolites, form a predictive model to diagnose prostate cancer that has shown encouraging results.
- 23 November 2023
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 20 (2) , 244-252
Comparison between open and minimally invasive pyeloplasty in infants: A systematic review and meta-analysis
- 23 November 2023
- Published by Elsevier in Journal of Pediatric Urology
- Vol. 20 (2) , 244-252
Comparison between open and minimally invasive pyeloplasty in infants: A systematic review and meta-analysis
- 1 October 2021
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 43 (4) , 708-717
TESE-ICSI outcomes per couple in vasectomized males are negatively affected by time since the intervention, but not other comorbidities
- 1 October 2021
- Published by Elsevier in Reproductive BioMedicine Online
- Vol. 43 (4) , 708-717
TESE-ICSI outcomes per couple in vasectomized males are negatively affected by time since the intervention, but not other comorbidities